Cocrystal Pharma Inc
(NASDAQ : COCP)

( )
COCP PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Generic
symbolcompany%chnglast%shortavg$volume
AGNAllergan plc
-1.74%149.732.8%$351.38m
ZTSZoetis, Inc. Class A
1.02%89.831.9%$203.25m
TEVATeva Pharmaceutical Industries Limited Sponsored ADR
1.35%18.772.1%$191.71m
MYLMylan N.V.
-2.24%29.623.2%$129.71m
TXMDTherapeuticsMD, Inc.
-2.98%4.2325.3%$11.98m
RDYDr. Reddy's Laboratories Ltd. Sponsored ADR
1.17%37.202.0%$11.25m
ABEOAbeona Therapeutics, Inc.
-11.54%7.977.9%$5.77m
TAROTaro Pharmaceutical Industries Ltd.
-1.23%88.366.3%$4.23m
LFVNLifeVantage Corporation
-1.33%14.153.3%$2.40m
PETXAratana Therapeutics, Inc.
-0.16%6.318.7%$1.70m
CPHIChina Pharma Holdings, Inc.
-1.23%0.250.1%$0.15m
JAGXJaguar Animal Health, Inc.
-8.57%0.309.8%$0.10m

Company Profile

Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the company has a pipeline of early preclinical programs. Cocrystal Pharma was founded on January 2, 2014 and is headquartered in Tucker, GA..